N- and S-oxygenation activity of truncated human flavin-containing monooxygenase 3 and its common polymorphic variants

• Published in: Archives of biochemistry and biophysics 2021-01, Vol.697, p.108663-108663, Article 108663
• Main Authors: Bortolussi, Stefania, Catucci, Gianluca, Gilardi, Gianfranco, Sadeghi, Sheila J.
• Format: Article
• Language: English
• Subjects: Biocatalysis; Drug metabolism; Flavin-containing monooxygenase; Flavoprotein; Humans; Models, Molecular; Oxidation-Reduction; Oxygen - metabolism; Oxygenases - chemistry; Oxygenases - genetics; Oxygenases - metabolism; Polymorphic variants; Polymorphism, Genetic; Protein Conformation; Truncation
• ISSN: 0003-9861; 1096-0384
• DOI: 10.1016/j.abb.2020.108663

Human flavin-containing monooxygenase 3 (FMO3) is a membrane-bound, phase I drug metabolizing enzyme. It is highly polymorphic with some of its variants demonstrating differences in rates of turnover of its substrates: xenobiotics including drugs as well as dietary compounds. In order to measure its in vitro activity and compare any differences between the wild type enzyme and its polymorphic variants, we undertook a systematic study using different engineered proteins, heterologously expressed in bacteria, purified and catalytically characterized with 3 different substrates. These included the full-length as well as the more soluble C-terminal truncated versions of the common polymorphic variants (E158K, V257M and E308G) of FMO3 in addition to the full-length and truncated wild-type proteins. In vitro activity assays were performed with benzydamine, tamoxifen and sulindac sulfide, whose products were measured by HPLC. Differences in catalytic properties between the wild-type FMO3 and its common polymorphic variants were similar to those observed with the truncated, more soluble versions of the enzymes. Interestingly, the truncated enzymes were better catalysts than the full-length proteins. The data obtained point to the feasibility of using the more soluble forms of this enzyme for in vitro drug assays as well as future biotechnological applications possibly in high throughput systems such as bioelectrochemical platforms and biosensors. •Engineered C-terminal truncated versions of common FMO3 polymorphic variants.•Truncated FMO3 proteins are more soluble than full-length proteins.•Truncated and full-length polymorphic variants display similar activity trends.•Truncated FMO3 variants are better catalysts of N- and S-oxygenation reactions.